Plasma was Haemonetics’s largest segment in fiscal 2026, bringing in $524.46M of $1.10B (48%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma | $499.92M | $569.54M | $535.43M | $524.46M | |||||||||||||
| Plasma Products & Services | — | — | — | — | |||||||||||||
| Blood Center Disposables | — | — | — | — | |||||||||||||
| Hospital | $254.99M | $282.00M | $309.25M | $354.30M | |||||||||||||
| Hospital Products & Services | — | — | — | — | |||||||||||||
| Plasma Disposables | — | — | — | — | |||||||||||||
| Blood Center | $207.62M | $211.17M | $213.13M | $220.86M | |||||||||||||
| Blood Center Products & Services | — | — | — | — | |||||||||||||
| Whole Blood | — | — | — | — | |||||||||||||
| Platelet | — | — | — | — | |||||||||||||
| Cell Processing | — | — | — | — | |||||||||||||
| Surgical | — | — | — | — | |||||||||||||
| Hemostasis Management | — | — | — | — | |||||||||||||
| Software Solutions | — | — | — | — | |||||||||||||
| Equipment &Amp; Other | — | — | — | — | |||||||||||||
| Equipment & Other | — | — | — | — | |||||||||||||
| Red Cell | — | — | — | — | |||||||||||||
| Orthopat | — | — | — | — | |||||||||||||
| Diagnostics | — | — | — | — | |||||||||||||
| Service | — | — | — | — | |||||||||||||
| Total | $962.53M | $1.06B | $1.06B | $1.10B |
Haemonetics brought in $1.10B from its three segments in fiscal 2026, the year ended March 28, 2026. That is less than the $1.33B it reports by statement business segments, so these segments do not cover all of its revenue. Plasma was the largest at $524.46M (47.7%), ahead of Hospital at $354.30M (32.2%) and Blood Center at $220.86M (20.1%).
Compared with fiscal 2025, Hospital grew fastest, up 14.6% to $354.30M, while Plasma fell the most, down 2.0% to $524.46M.
Plasma was Haemonetics’s largest segment in fiscal 2026, bringing in $524.46M of $1.33B (39%).
| Statement Business Segments | FY 2010 | FY 2011 | FY 2012 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|
| Plasma | $499.92M | $569.54M | $535.43M | $524.46M | ||||
| Hospital | — | — | $564.27M | — | ||||
| Blood Center | — | — | $261.12M | — | ||||
| Blood Management Technologies | $254.99M | $282.00M | — | $354.30M | ||||
| Hemostasis Management, Hospital | — | — | — | — | ||||
| Reportable | — | — | — | — | ||||
| Apheresis | $207.62M | $211.17M | — | $220.86M | ||||
| Interventional Technologies | $126.72M | $174.29M | — | $234.01M | ||||
| Interventional Technologies, Hospital | — | — | — | — | ||||
| Other, Hopsital | — | — | — | — | ||||
| Whole Blood | $79.42M | $72.06M | — | $406.00K | ||||
| Total | $1.17B | $1.31B | $1.36B | $1.33B |
Haemonetics brought in $1.33B from its five segments in fiscal 2026, the year ended March 28, 2026. Haemonetics regrouped these segments after fiscal 2025, so the total does not compare directly with that year's $1.36B. Plasma was the largest at $524.46M (39.3%), ahead of Blood Management Technologies at $354.30M (26.6%) and Interventional Technologies at $234.01M (17.5%). The other two segments brought in $221.27M combined.
From fiscal 2023 to 2026, combined revenue from these segments grew from $1.17B to $1.33B, a compound annual growth rate of 4.5%. Plasma's share of the total fell from 42.8% to 39.3%.
Haemonetics stopped reporting Hospital ($564.27M in fiscal 2025) and Blood Center ($261.12M in fiscal 2025) as separate segments.
United States was Haemonetics’s largest region in fiscal 2026, bringing in $982.18M of $1.33B (74%).
| Geography | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $842.90M | $970.01M | $1.01B | $982.18M | |||||||||
| Europe | $156.68M | $160.14M | $175.66M | $185.02M | |||||||||
| Rest Of Asia | $104.14M | $107.54M | $92.31M | $87.21M | |||||||||
| Asia | — | — | — | — | |||||||||
| Japan | $61.30M | $58.09M | $62.41M | $68.20M | |||||||||
| Plasma | — | — | — | — | |||||||||
| Other | $3.65M | $13.28M | $19.54M | $11.42M | |||||||||
| Other Country Or Region | — | — | — | — | |||||||||
| All Other | — | — | — | — | |||||||||
| Total | $1.17B | $1.31B | $1.36B | $1.33B |
Haemonetics brought in $1.33B from its five regions in fiscal 2026, the year ended March 28, 2026. That was down 2.0% from $1.36B in fiscal 2025. United States was the largest at $982.18M (73.6%), ahead of Europe at $185.02M (13.9%) and Rest Of Asia at $87.21M (6.5%). The other two regions brought in $79.62M combined.
Compared with fiscal 2025, Japan grew fastest, up 9.3% to $68.20M, while Rest Of Asia fell the most, down 5.5% to $87.21M. From fiscal 2023 to 2026, combined revenue from these regions grew from $1.17B to $1.33B, a compound annual growth rate of 4.5%. United States' share of the total rose from 72.1% to 73.6%.
Haemonetics (HAE) reports its revenue by segment, by statement business segments and by geography. In fiscal 2026, Plasma was its largest segment, bringing in $524.46M (47.7% of the total), followed by Hospital at $354.30M (32.2%).
Plasma was Haemonetics' largest segment in fiscal 2026, bringing in $524.46M, or 47.7% of the $1.10B total across its three segments.
United States was Haemonetics' largest region in fiscal 2026, bringing in $982.18M, or 73.6% of the $1.33B total across its five regions.
Among Haemonetics' segments that make up at least 2% of revenue, Hospital grew fastest in fiscal 2026, up 14.6% from $309.25M to $354.30M.
Every figure comes from Haemonetics' annual financial filings, as reported. Each line keeps the name Haemonetics gives it, and years follow its fiscal calendar.
Haemonetics' revenue by segment goes back to fiscal 2010, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.